ストックスクリーナーアプリを入手
8.80
1.15%
0.10
前日終値:
$8.70
開ける：
$9
24時間の取引高:
4,293
Relative Volume:
0.02
時価総額：
$8.07M
収益：
-
当期純損益:
$-34.66M
株価収益率:
-0.0902
EPS:
-97.5284
ネットキャッシュフロー:
$-19.52M
1週間 パフォーマンス:
+7.19%
1か月 パフォーマンス:
-9.09%
6か月 パフォーマンス:
-42.22%
1年 パフォーマンス:
+15.33%
1日の値動き範囲:
$8.61
$9.00
1週間の範囲:
$7.88
$10.30
52週間の値動き範囲:
$6.0829
$22.03
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.80 | 8.07M | 0 | -34.66M | -19.52M | -97.53 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Transcode Therapeutics Inc (RNAZ) 最新ニュース
(RNAZ) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TransCode Therapeutics 2025 10-K: Advancing RNA and Immuno-Oncology Cancer Therapeutics with Proprietary TTX Platform - Minichart
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) expands cancer pipeline with Polynoma and Unleash deals - Stock Titan
RNAZ News | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding - Stock Titan
Market Overview: How sensitive is TransCode Therapeutics Inc to inflationWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 8-KCurrent report - ADVFN
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
TransCode Therapeutics Delays 2025 Annual Filing - The Globe and Mail
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
Growth Value: Is TransCode Therapeutics Inc showing insider buying2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Gap Down: Is TransCode Therapeutics Inc subject to activist investor interestAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Volume: What are analysts price targets for TransCode Therapeutics IncDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Mood: Does TransCode Therapeutics Inc have pricing power2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Bond Watch: Whats the outlook for TransCode Therapeutics Incs sector2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily
Portfolio Update: Will TransCode Therapeutics Inc benefit from sector rotation2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
Is TransCode Therapeutics Inc undervalued by DCF analysis2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Breakout Zone: Should I hold or sell TransCode Therapeutics Inc now2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Aug Chart Watch: Is TransCode Therapeutics Inc showing insider buyingWeekly Profit Summary & Momentum Based Trading Ideas - baoquankhu1.vn
The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily
RNAZ Should I Buy - Intellectia AI
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
Transcode Therapeutics Inc (RNAZ) 財務データ
収益
当期純利益
現金流量
EPS
2.19%
0.43%
大文字化:
|
ボリューム (24 時間):